Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Eqrx

Evaluate

Thumbnail
March 23, 2023

Merkel cell provides Incyte’s laggard a way in

March 08, 2023

The ink dries on the blank cheque craze

As Apexigen throws in the towel six months after listing, can any bright spots be found in the stats on Spacs?

Article image
Vantage logo
December 20, 2022

Biotech’s key upcoming clinical results

Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.

Article image
Vantage logo
November 10, 2022

U-turn confirms that the US cut-price oncology model is dead

EQRX tears up plans to challenge US PD-(L)1 players on price, and switches focus to two non-discounted small molecules.

Article image
Vantage logo
September 09, 2022

Clinical showdown in immuno-oncology

The latest edition of the PD(L)anner provides key updates and details upcoming global events in immuno-oncology.

Article image
Vantage logo
May 03, 2022

China-backed US approvals continue to hang in the balance

Article image
Vantage logo
February 11, 2022

How China applicants could avoid the sintilimab scenario

A US adcom savages sintilimab, but the biggest problems identified might be sintilimab-specific.

Article image
Vantage logo
February 08, 2022

Bavencio’s forgotten lung cancer readout is a dud

Article image
Vantage logo
January 05, 2022

In 2021 it paid to stay private when the chips were down

While biotech indices fell, 2021 saw private companies raise the largest amount of venture capital ever.

Article image
Vantage logo
January 04, 2022

Days of reckoning for immune checkpoint blockers

Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.

Article image
Vantage logo
December 06, 2021

Benevolent AI aims to defy Spac doom

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up